Rocket Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held on June 18, 2025. Rocket Pharmaceuticals, Inc. (RCKT) is a Delaware corporation listed on The Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a current report focused solely on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing approximately 85.56% of eligible shares (91,366,461 shares) participated in the meeting. All three proposals were approved:
- Proposal One (Election of Directors): Ten directors were elected. While all nominees received majority support, David P. Southwell received the highest number of "Votes Withheld" (23,786,280) compared to other nominees.
- Proposal Two (Ratification of Auditors): Stockholders ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025.
- Proposal Three (Executive Compensation): The non-binding advisory vote on executive compensation was approved.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the specific reasons for the significant number of votes withheld for director nominee David P. Southwell.
- Confirm the total number of outstanding shares to contextualize the 85.56% participation rate.
- Review the 2025 Proxy Statement for detailed executive compensation data referenced in Proposal Three.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial metrics.